Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of a combined treatment with Sorafenib (Nexavar®) and
pegylated interferon-α-2b (PegIntron®) in patients with malignant melanoma in stage IV.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Schleswig-Holstein University of Schleswig-Holstein